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I " ~  Combined Antlplstslet Therapy WHhout 
Antic~agulation After Stent Implantation; The 
Ticlopldine Aspirin Stent Evaluation (TASTE) Study 
Jean-Marc Lablanche, Jeen-Louis Bonnet, Gilles Grollier, Nicolas Oanchin, 
Marc Bedosoa, Chdatophe Leciorcq, Alec Vahanian, Michel E. Bertrand. 
University of Lille, France 
Despite intensive anttcoagulation, subacute stent hrombosis and major hem- 
orrhagio complications remain major problems after stent implantation. 
In a pr0epactive multicenter French study, we investigated the efficacy of 
a combination of 2 antiplateiot agents, ticlopidine 500 ~ and aspidn 200 mg 
daily, without oral anticoegulation after stent implantation. Since November 
1993, 529 consecutive patients (545 vessels) were sucCeSSfUlly stented with 
conventional (non.bapadn coated) stents, for failed angioplasty (n = 112), a 
suboptimal result (n = 326), or electivaly (n == 107). We present he in-hospital 
and 4 week clinical follow-up results. 
Coronary events related or possibly related to stent thrombosis occurred in 
5.4% of patients with bailout stents, 1.8% of patients with stenla for suboptimal 
msufts. Serious blesd!irl~l-occurred in 5.4% of patients efter bailout stenting. 
Neither stont hrombosis nor seflous bleeding occurred after elective stenting. 
"liclopidine was discontinued in 1,2% of patients due to neutrepenie (0.6%) 
or rash (0.6%). Mean hospital stay decreased from 6.16 :l: 2.14 d~ys to 4.2 
4- 2.15 days during the study period. 
A combination of 2 antiplatslet agents can be employed in the vast majority 
of patients after coronary slant implantation. Supacute stent hrombosis rates 
and bleeding complications compare f'avourably ~ those reported using 
conventional therapy and the duration of hospitalisation isreduced, 
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Preliminary Results of the Must Trial. Major Clinical 
Events During the First Month 
M,C. Morioe, B. Valeix, J. Marco, J,J, Goy, P, Commeau, N, ReilarL 
V. Voudds, A. Serfs, T. Baardman. P.W Serruys I.C. V Paris Sud, France 
Intrecoronary stents am increasinly being used as an adjunct or alternative 
to balloon angioplaaty. Its major limitation is the intrinsic thromboenisity of 
metslllo stent. The French registry on coronary stenting without Go- - in  
showed a low rate of subacute thrombosis and bleeding complication with 
the association of 2 antiagmgants (Ticfopidlne and aspidn). The MUST study 
was designed to validate the concept of stenting with Ticlap~ne 250 mg 
for one month and espidn 100 rag/day for 6 months as sole post stenting 
treatment. 
In this open, pmspechva, multicentar, ~3senm,~o~d study, 21 European 
contem enrolled 2~0 patients from January tO August 1995. Patients elected 
had stable or unstable angina and were tmaled with a single 15 mm Palmaz- 
Sct~dz stont deployed on e native artory of 3 mm or moro. Only de novo 
lesions were included. 
Results: Major' adverse events dudng the fi~t month were one case of 
emergent sufgelry (0A%), 3 cases of subacute thrombosis (1.2%) and 5 M,I 
(1.S%). Seven patients (2.7%) experienced at least one major ar~'~rse event. 
In conclnsio~: com~Iry s~enting with low doses o F . B ~  is 
foasbfo and efflcte~ It ~e~-esents a low cost approach using conve~monat 
stonts, wmmut Nus guyed stent depkwmenL 
9:00 
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Antiplatelet Regimens Following Coronary Artery 
menting 
Chfistophsr M, Goods, Khaled F. Al-Shalbi, Brian H. Negus, Ming W. Uu, 
Sanjay S. Yadav, Suresh R Jain, Larry S. Dean, Sfiram S. lyer, J. 
Michael Parks, Gary S. Roubin, University of Alabama at Birmingham, 
Birmingham, AL 
Antiplatelat therapy with Aspirin and Ticfopldine has been associated with low 
thrombosis rates following corona~ artery stenting. It is unknown if similar 
outcomes could be achieved with Aspidn alone. Between 9/94 and 8/95 342 
patients were selected to receive one of two antiplatefot regimens following 
native coronary artery stenting using the Cook stent. Patio.is were selected 
after optimal anglog~ic results were achieved, Intravasoular ultrasound 
guidance was not use~l. Group A (n = 296) were p~ents Ireated with a 
combination of Aspidn 325 mg BID and T~opidine 250 mg BID and Group B 
(n : 46) were patients treated with Aspirin 325 mg BID alone. Assignment to 
either regimen was based on physician preference. Clloieal outcomes with 
30 day follow-up am shown. 
A (n = 296) B (n = 46) P value" 
Stent hrombosis 2 (0.7%) 3 (6,6%) 0.02 
Death 1 (0.3%) 2 (4.4%) 0.05 
Bypass u ,rg?W 2 (0.7%) 0 NS 
* Fisher Exact est wflh pemada~on melhod 
Conclusion: This non-randomized, compara~ve study suggests that 
combination of Aspirin and Ticlopidine is superior to Aspirin efone in prevent- 
ing stent thrombosis. 
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Palmaz-Schallz Stent Placement-6-Month Fol low-up 
Albert Schemig, Halmut SchOhlen, Rudolf Blasini, Adnan Kaslmti, 
Hanna Waiter, Martin Hedamitzky, Eva Zdzreann, Gert Rlohardt, 
Claus Schmitt, Eckhard Nt, Franz-Josef Neumann. I. Medizinische Klinik, 
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Recent studies have advocated the feasibility of antiplatelet therapy alone to 
prevent hrombotic occlusions after coronary stellt placement. The goal of our 
randomized Vial is to compare anttcoagula6nn therupy with antipfotelat ther- 
apy after su,:,~-s=,~ul Palmaz~T.~chatz s ent placement. The poSUntswenlion 
armT(oagulation protocol consists of aspirin (100 mg bid) + phenlxocoumon 
with i.v.-hepadn until the target INR of 3.5 is reached, The an~protsco l  
consists of aspidn (10~ mg bid) + ticfopidina (250 mg bid). Phenprocoumon 
and ticlupidina m both given for four weeks. Randomization started October 
1, 1994 to continue for one year. Analysis will include defined endpolots 
of cardiac (death, Infection, occlusion of the stentsd vessel, repeat PTCA, 
CABG), non cardiac events (groin complications or bleeding requiring surgery 
or transfusion, or impaldng organ function) and angiegmphlo utcome. By 
August 31,1995 473 patients hed been randondzed. 
Analysis of the two treatment ~ for clinical events during a 30 day 
and 6 month follow Up period and an~hlc  6 month outcome will be 
present~. 
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In-Hospital and l~ lonth  Clinical Results Of~n t t Intsmattonal Study Testing the Concept o! IVU~. 
Peter de Jasgere, Harald Mudra. Ymon Nmagor, Hans Flgufl~ lan Penn, 
Seine Deus~ Am~o Barren(, Ct~st~n Ha .~ ~ the Mu'~c S~Y 
,~st~fo~.  Roa~e~am, The ~ 
A ~e ~er  ~ de~n~ra~d th= ~ ant~a~on can 
safoly be omitlad alter i~-a,~,~-ona,'y ~ provided ~ stent expan- 
sk~ ~ olr,~-~ ~ ~ h~h presume bano~s ~d WUS gu~anoe. Th~ 
c.~-.:~t is vandated In a rnsgk:ent~ approach by using an open. ProSPe'> 
tire, ~- -~:  study (MUS~ Study). For th~ ~ ,  the h-~;-,~¢e of 
